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Background: Directly Observed Treatment Short course (DOTS) strategy is aimed at diagnosing 70% of
infectious tuberculosis (TB) and curing 85% of it. Arsi Zone of Ethiopia piloted DOTS strategy in 1992. Since
then, the trend in treatment outcomes in general and at district-level in particular has not been assessed. The
aim of this study was to analyse the trend in TB treatment outcomes and audit district-level treatment
outcomes in the 25 districts of Arsi Zone.
Design: A retrospective cohort study design was employed to audit pulmonary smear-positive (PTB)
patients registered between 1997 and 2011. Demographic and related data were collected from the TB unit
registers between January and March 2013. The 15-year trend in treatment outcomes among PTB patients
and district-level treatment outcomes was computed.
Results: From 14,221 evaluated PTB cases, 11,888 (83.6%) were successfully treated. The treatment success
rate (TSR) varied from 69.3 to 92.5%, defaulter rate from 2.5 to 21.6%, death rate from 1.6 to 11.1%, and
failure rate from 0 to 3.6% across the 25 districts of the zone. The trend in TSR increased from 61 to 91% with
the increase of population DOTS coverage from 18 to 70%. There was a declining trend in defaulter rate from
29.9 to 2.1% and death rate from 8.8 to 5.4% over 15 years. Patients aged 2549 years (Adjusted Odd Ratio
(AOR), 0.23; 95% CI: 0.210.26) and ]50 years (AOR, 0.43; 95% CI: 0.320.59), re-treatment cases (AOR,
0.61; 0.41, 0.67), and TB/HIV co-infection cases (AOR, 0.45; 95% CI: 0.310.53) were associated with
unsuccessful treatment outcomes.
Conclusions: DOTS expansion and improving population DOTS coverage in Arsi has led to a significant
increase in treatment success and decrease in death and defaulter rates. However, there is a major variation in
treatment outcomes across the 25 districts of the zone, so district-specific intervention strategy needs to be
considered. The low TSR among re-treatment cases might be due to the high rate of MDR-TB among this
group, and the issue needs to be further investigated to identify the extent of the problem.
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A
lthough effective treatment has been used to treat
tuberculosis (TB) for several decades, TB re-
mains a major global health problem and the
second leading cause of death worldwide. In 2010, from
the estimated 8.8 million incidents of TB cases, 5.7
million TB cases and 1.4 million deaths were reported
globally (1, 2). It was also found out that poor adherence
and irregular TB treatment leads to an increase in the
period of infection with the consequences of multi-drug
resistance TB (MDR-TB) (3, 4).
The World Health Organization (WHO) recommended
Directly Observed Treatment Short course (DOTS) (5, 6),
which aims at detecting 70% of infectious cases and
curing 85% of them. This strategy is expected to interrupt
transmission of the disease and reduce the number of
infected individuals and the period of infectiousness (4).
In 2011, Ethiopia ranked seventh among the 22 high
burden countries in terms of estimated number of TB
cases (7, 8). Moreover, TB is the third leading cause of hos-
pital admission and the second cause of deaths in Ethiopia
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(page number not for citation purpose)(7, 9). In 1992, DOTS strategy started in Ethiopia where
Arsi and Bale zones of Oromia region were the first two
to be selected for piloting. Since 1997, DOTS has been
scaled up to include the entire country (10).
Different studies from southern and northern parts of
Ethiopia show that the implementation and expansion of
DOTS strategy improved the TB treatment success rate
(TSR) and reduced defaulter rates (5, 1113). Never-
theless, a study from northern Ethiopia indicated that
TSR under DOTS strategy was low with high proportion
of deaths and defaulters (14).
Although Arsi wasthefirstzone tostart DOTS strategy
in Ethiopia, no investigation has been made to see if there
are differences in TB treatment outcomes across the dis-
tricts in the zone and also the trend in TB treatment
outcomes over the years. Few studies analysed the trends
in treatment outcomes as aggregate at either regional or
national level. However, to the knowledge of the authors,
none of these studies investigated district-specific treat-
ment outcomes to see if there is variation in treatment
outcomes across districts in the country (5, 11, 12, 14, 15).
Hence, the aim of this study was to analyse trends in TB
treatment outcomes over 5 years in the 25 districts of Arsi
Zone and to investigate if there were differences in the
outcome across the districts.
Methods
Study setting
The study was conducted in the Arsi Zone, Central
Ethiopia. The zone has one hospital and 73 health centres
in 25 districts with a total population of 3.1 million.
About 89% of the zonal population resided in rural areas.
In 2011, about 70% of the population lived within a 10-
km radius or at a walking distance of 2 hours from a
health institution and thus had access to DOTS service
(16). In 2004, the government of Ethiopia, under the
health extension package programme (HEP), launched a
community-based essential health service to the community.
The HEP is implemented through the deployment of
health extension workers (HEWs) at a community level
(17). A 1-year undergraduate and two new female cadres
are deployed as community health workers at every kebele
(the smallest government administrative unit) with the
responsibility of providing essential health services for
a population of 5,000. The objective of HEP is to ensure
equitable access to health services, prevent major com-
municable diseases, and promote health in the community.
As part of their role in the prevention of communicable
diseases, HEWs are trained on how to identify and refer
TB suspects, provide health education and treatment, and
trace defaulters (18).
Since 1997, DOTS programme, which started piloting
in one health centre and a hospital, has significantly
expanded and subsequently gained full integration into
74 health facilities at the end of 2011. All health facili-
ties were utilised as TB diagnostic and treatment units
used standard TB unit registers from the National
Tuberculosis and Leprosy Control Programme (NTLCP)
to register TB cases. Since 2008, TB patients were offered
services of provider initiated voluntary counselling and
testing for HIV.
The TB drugs used in combination were isoniazid (H),
rifampicin (R), pyrazinamide (Z), ethambutol (E), strep-
tomycin (S), and thioacetazone (T). However, since 1997
thioacetazone was removed from the system and not
used any more. Using the NTLCP guidelines (9), all new
patients were treated with RHZE or S for 2 months
followed by EH or RH for 6 months. The first 2 months
of intensive phase treatment were under direct super-
vision of the health workers. During this phase, with the
exception of those who were critically sick, TB patients
received treatment on an ambulatory basis. Re-treatment
cases were treated with SERHZ for 2 months, ERHZ for
another 1 month, and ERH for 5 months (9).
Study design and data collection
Retrospective cohort study design was employed to audit
TB treatment outcomes for PTB patients treated in the
25 districts of Arsi Zone. Pulmonary smear-positive TB
cases registered between September 1, 1997, and August
31, 2011, for TB treatment in all public health institutions
(73 health centres and one hospital) were included in the
study. The principal investigator identified all TB unit
registers used in each TB treatment unit during the study
period. The total number of TB unit registers in each TB
treatment unit over the study period was checked against
the total number of annually reported TB cases from
each TB treatment unit to the district health office to see
if there was any missing TB unit register. Indeed, no
missing TB unit registers were detected during the study
period. After the identification of all TB unit registers
from TB treatment units, the principal investigator col-
lected them between January and March 2013. Ten
trained data collectors gathered from TB unit registers
socio-demographic and related data like type of TB, TB
patient category, contact person for tracing, date of
treatment initiation, drug regimen, treatment follow-up,
follow-up sputum smear microscopic result, HIV status,
treatment outcomes, and date DOTS started in each
health institution.
Definitions of terms
Type of TB and treatment outcome were defined
according to the NTLCP guideline adopted from WHO
and a previous study report (15, 18).
Measurements
The area of residence, sex, age, HIV status, TB patient
category, treatment regimen, and history of contact
person for tracing were taken as independent variables
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dependent variable (15-year average treatment outcomes)
of each district was computed from the sum of annual
TSR of 15 years for each district (nominator) divided by
15 (denominator), which is the number of years of the
study period. The trend in PTB treatment outcomes of
the zone was computed from the sum of the annual
PTB treatment outcomes of the 25 districts in the zone
for each year of the study period. Comparison of 15-year
average treatment outcomes among districts was also
made after computing the 15-year average of treatment
outcomes for PTB cases for each district in the zone.
Moreover, a comparison of treatment outcomes between
the new and the re-treated PTB cases was also made.
Population DOTS coverage of the zone was also cal-
culated as the total number of the population residing
within a 10-km radius or 2 hours walking distance from
a public health institution as nominator and the total
number of population of the zone in each year as de-
nominator multiplied by 100. The National Health Ser-
vice standard where one health centre is expected to serve
25,000 people and one hospital to serve 250,000 people
was used to calculate population DOTS coverage (19).
A total of 521 PTB patients with incomplete records on
their treatment information and 628 who were trans-
ferred out to other health institutions out of the zone
were excluded from the analysis (Fig. 1).
Statistical analysis
Data were coded and double entered by 10 trained data
clerks using Epi-Info version 7. We used IBM SPSS
version 20 for data checking, cleaning, and analysis.
Descriptive analyses such as frequency, mean, and stan-
dard deviation were computed as appropriate. The ana-
lyses of linear trend for TSR, cure rate, defaulter rate, and
death rate were analysed, and statistical significance was
cheeked using X
2 for trend. Bivariate and multivariate
logistic regression analysis was used to determine the
associationbetweenindependentanddependentvariables.
Variables with pB0.2 in bivariate analysis were fitted into
the final multiple logistic regression models. Variables
with pB0.05 in the final model were taken as significant
determinants. The model adequacy and co-linearity as-
sumptions were checked using F-test and assessed for
normality by displaying continuous data on a histogram.
All numerical datawere found to be normally distributed.
Multi-co-linearity of the independent variables was
Successfully treated = 11,888(83.6%)
Unsuccessfully treated=2,333 (16.4%)
Excluded from the analysis
Total evaluated cases with category (n=14,221)
Total PTB+ cases registered during the study
period = 15,370 PTB+
Cured =9,608
(67.6%)
Treatment completed= 2,280(16%)
Died =1,048(7.4%) Defaulter =1,215(8.5%) Failure= 70 (0.5%)
New =13,237 (93.1%)
Relapse =867 (6.1%)
Incomplete record =521
Transferred out=628
Failure =51 (0.4)
Return for treatment after default ing = 66 (0.55)
Fig. 1. Proﬁle for pulmonary smear-positive TB patients registered during 19972011 and treatment outcomes, Arsi Zone,
Central Ethiopia.
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of 0.6 or less were used in model fitting.
Ethical approval
An Institutional Review Board of Oromia Regional State
Health Bureau, Ethiopia, approved the research for
scientific and ethical integrity. Formal permission to use
data in the study was obtained from the heads of Zonal
and District Health Offices and Health Institutions.
Results
Patient characteristics
A total of 15,370 PTB patients were registered in 25
districts of Arsi Zone between September 1997 and
August 2011. Of these, the treatment outcomes of 14,221
(92.5%) were evaluated. The treatment outcomes of 521
PTB patients with incomplete records and 628 trans-
ferred out, and hence with unknown treatment outcomes,
were excluded from the analysis. From the total evaluated
TB cases, 7,734 (54.4%) were males while the remaining
were females, and 5,119 (34%) were urban residents. The
age of the patients ranged from 1 to 98 years with a mean
(standard deviation) of 28.7 (15.3%) years. The majority,
13,237 (93.1%), of the TB patients were new whereas 867
(6.1%) were relapse; 51 (0.4%) were failure; and 66 (0.5%)
were return after default. This makes a total of 984 (6.9%)
re-treatment cases (Table 1 and Fig. 1).
Trend over time
The trends in the TB TSR among PTB cases increased
from 61.3% in 1997 to 91.2% in 2011 with an increase in
population DOTS coverage from 18% in 1997 to 70% in
2011. The overall TSR increased by 30% and population
DOTS coverage by 52% over 15 years (X
2 trend31. 08,
pB0.001). The TSR and cure rate steadily increased with
DOTS site expansion through the years between 1997
and 2001 with the exception of 1999 when a decline was
observed. However, the increasing trend over time in TSR
stabilised in the range between 82.1 and 84.2% during the
years20032008andthenincreasedto91.7%in2011(Fig.2).
The trendindeathrate amongPTBcasesremained in
thehighrangeof12.58.8% duringthefirst7 years(1997
2005) of DOTS implantation in the study area. The
highest death rate (12.5%) was observed in 1999 followed
by 11.8% in 2000. However, the trend in death rate gra-
dually declined from 5.7 to 3.9% during the last 5 years of
the study period (20082011). The trend in defaulter rate
also declined steadily from 29.9 to 2.1% over 15 years
(19972011) (X
2 trend18.56, pB0.001) (Fig. 2).
Treatment outcomes
The treatment outcomes of 14,221 pulmonary smear-
positive TB caseswere evaluated. Of these, 11,888 (83.6%)
were treated successfully, 9,608 (67.5%) were cured, and
2,333 (16.4%) were treated unsuccessfully. From those
treated unsuccessfully, 1,048 (7.4%) died, 1,215 (8.5%)
defaulted, and 70 (0.5%) had treatment failure (Table 2).
The TSR was higher (84.8%) among new PTB
patients compared to re-treatment cases (67.5%). This
wasmainlydueto thehighrate ofdeath (11.7%), defaulter
(19.2%) and failure (5.6%) among the re-treatment cases.
Pulmonary smear-positive new TB cases had higher TSR
compared to re-treated PTB cases after relapse (84.8%
vs. 68.4%); return after default (84.8% vs. 57.6%); and re-
treated cases after failure (84.8% vs. 66.7%) (pB0.01). On
the contrary, death rates were higher among PTB cases
that returned after default (15.2%); re-treated cases for
pervious failure (15.7%); and re-treated cases for previous
relapse (11.2%) compared to new PTB cases (7%)
(pB0.01) (Table 2).
The defaulter rate among PTB cases that returned
after defaulting treatment was high (26.6%), and such
patients were more likely to default again compared to
new PTB cases (7.8%) (pB0.01). On the other hand,
PTB patients re-treated for previous failure had higher
treatment failure (7.8%) and were more likely to have
Table 1. General characteristics of pulmonary smear-
positive TB cases registered for treatment between 1997
and 2011, Arsi Zone, Central Ethiopia
Characteristics Number Percentage
Sex
Male 7,734 54.4
Female 6,487 45.6
Age group
014 1,939 13.6
1524 4,389 30.9
2549 6,207 43.6
]50 1,686 11.9
Mean age (Standard Deviation) 28.7 (15.3)
Area of residence
Urban 5,119 34
Rural 9,102 66
Patient category
New 13,237 93.1
Relapse 867 6.1
Failure 51 0.4
Return for treatment after defaulting 66 0.5
TB/HIV co-infection (n3,627 tested)
by type of TB
288 7.9
Treatment outcomes
Cured 9,608 67.5
Treatment completed 2,280 16
Successfully treated (cured and
treatment completed)
11,888 83.6
Died 1,048 7.5
Defaulted 1,215 8.5
Failed 70 0.5
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(0.4%) (pB0.01) (Table 2).
Factors associated with unsuccessful TB treatment
outcomes
Logistic regression analyses revealed that patients who
are urban residents, older ones, re-treated cases, those co-
infected with HIV, and those with no contact person were
less likely to be treated successfully. In the final model,
TB patients in the age group 2549 (AOR, 0.26; 95% CI:
0.530.95) and above 50 years of age (AOR, 0.42; 95%
CI: 0.330.60) were less likely to be treated successfully
compared to the younger age groups. Moreover, re-
treatment cases (AOR, 0.61; 0.41, 0.67) in comparison
with new ones, and TB/HIV co-infected cases (AOR,
0.45; 95% CI: 0.310.53) in comparison with non-TB/
HIV co-infected ones were less likely to be successfully
treated (Table 3).
Treatment outcomes among PTB cases by district
The overall treatment outcomes among PTB cases
registered for treatment during the study period varied
across the 25 districts of the zone (X
2317. 35, pB
0.001). The 15-year average TSR varied from 69.3 to
Fig. 2. Trends in TB treatment outcomes and population DOTS coverage, Arsi Zone, Central Ethiopia, 19972011.
Note: Trends in treatment success rate of PTB increased (X
2trend 31.08, pB0.001) with declined in death rate
(X
2trend18.56, pB0.001) and defaulter rate (X
2trend33.74, pB0.001) over time. Trends in treatment success rate
increased; death rate and defaulter rate declined with increase of DOTS population coverage (X
2trend22.243, pB0.001).
Table 2. Treatment outcomes of new smear-positive and re-treatment pulmonary TB cases of Arsi Zone, Central Ethiopia,
19972011
Treatment outcomes
Cured
Treatment
completed
Successfully
treated Died Defaulted Failed
Unsuccessfully
treated
Variable No % No % No % No % No % No % No % Total
New (N) 9,085 68.6 2,138 16.2 11,223 84.8 933 7.0 1,026 7.8 55 0.4 2,014 15.2 13,237
Relapse (R) 468 54.0 125 14.4 593 68.4 97 11.2 167 19.3 10 1.2 274 31.6 867
Defaulter (D) 26 39.4 12 18.2 38 57.6 10 15.2 17 25.8 1 1.5 28 42.4 66
Failure (F) 29 56.9 5 9.8 34 66.7 8 15.7 5 9.8 4 7.8 17 33.3 51
Total 9,608 67.6 2,280 16.0 11,888 83.6 1,048 7.4 1,215 8.5 70 0.5 2,333 16.4 14,221
All re-treatment
cases (RDF)*
523 53.2 142 14.4 665 67.6 115 11.7 189 19.2 15 1.5 319 32.4 984
Note: Total cases for each category are the sum of successfully treated and unsuccessfully treated of each category. *The sum of relapse
(R), defaulter (D) and Failure (F).
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whereas death rate spanned from 1.6 to 11.1%. It was
also observed that districts with low TSR (69.3%) had
high rates of default (16.9%), death (10.2%), and failure
(3.6%) while those with high treatment success (more
than 85%) had low rates of default and death. Moreover,
high death rate was observed in districts that had high
TB/HIV co-infection (Table 4).
Discussion
Expanding DOTS and improving its population coverage
has increased TSR in PTB cases and has led to im-
proved overall TB treatment outcomes in the study area.
There are poor treatment outcomes among re-treatment
cases compared to the new ones. Further, there are sig-
nificant differences in TB treatment outcomes among
the 25 districts of the zone. These findings might help
the TB control programme managers and policy makers
to look for an alternative strategy for addressing the
inequality in TB treatment outcomes across different geo-
graphical settings in the country.
In this study, TB TSR increased significantly from
61.3 to 91.2% and parallel with the expansion of DOTS
population coverage from 18 to 70% in 15 years. The
upward trend in TSR was inversely proportional to the
declining trend in defaulters which went from 29.9 to
2.1% and deaths from 12.5 to 5.4% over time. Such a
result goes with findings by other studies that showed a
similar trend of increase in treatment success and decline
in death and default rate (5, 11, 20). Moreover, the in-
crease in TSR during the last 3 years of the study period
was significant and higher than the 85% target recom-
mended by WHO.
The TSR increased by 31% through the improvement
of population DOTS coverage by 52% in 15 years. This is
higher than the 13.4% rise in TSR and the 44% increase
in population DOTS coverage over 7 years in southern
Ethiopia (11). It is also higher than the 15% increase in
TSR over 14 years in Vietnam (20) and the 18% global
average increase gained in a 10-year period (21). The
increase in trend observed during the last 3 years of the
present study is significant and could be attributed to
the stepwise deployment of HEWs at community level.
Since 2008, it has been possible to cover all kebeles
through two female HEWs (19). The involvement of
HEWs in a TB control programme might have improved
access and played a significant role in the reduction of
defaulter cases. This implies the importance of further
decentralisation of DOTS service to the community level
where there are resource constraints and limited access to
health services to achieve MDG in TB control.
The overall 15-year average TSR among PTB
patients was 83.6%. This is high compared to findings
by previous studies which showed 29.5 and 28.3% in
northwest Ethiopia (14, 22), 55.7% in western Ethiopia
(23), and 77% in Tanzania (24). However, it is lower than
the 88% success rate in China (25) and 89% in southern
and northern Ethiopia (12, 26). The difference could be
due to variation in the length of the study period and the
sample size across different study areas. It could also be
due to variation in the study setting. Majority of the
patients in northern Ethiopia were from urban centres,
and about 25% of them were HIV co-infected (14, 22)
Table 3. Factors associated with TB treatment success rate among pulmonary smear-positive TB patients registered during
19972011 in Arsi Zone, Central Ethiopia
Treatment success categories
Variables Category Not successfully treated Successfully treated COR (95% CI) AOR (95% CI)
Patients’ residence Urban 794 (15.5) 4,325 (84.5) 1.00 1.00
Rural 1,138 (12.5) 7,964 (87.5) 1.49 (1.40,1.58)** 1.13 (0.96,1.37)
Age 014 years 192 (9.9) 1,747 (90.1) 1.00 1.00
1524 years 421 (9.6) 3,968 (90.4) 1.06 (0.95,1.21) 1.14 (0.84,1.53)
2549 years 1006 (16.2) 5,201 (83.8) 0.59 (0.52,0.68)** 0.74 (0.53,0.95)**
]50 years 325 (19.3) 1,361 (81.7) 0.47 (0.44,0.56)** 0.42 (0.35,0.60)**
Sex Male 1,060 (13.7) 6,674 (86.3) 1.00 1.00
Female 895 (13.8) 5,592 (86.9) 1.05 (0.98,1.11) 1.10 (0.94,1.30)
Patient category New 2,014 (15.2) 11,223 (84.8) 1.00 1.00
Re-treatment 319 (32.4) 665 (67.6) 0.47 (0.43,0.56)** 0.61 (0.41,0.67)**
HIV status HIV ve 227 (6.8) 3,112 (93.2) 1.00 1.00
HIV ve 49 (17.1) 239 (82.9) 0.35 (0.34,0.47)** 0.45 (0.31,0.53)**
Having, contact person Yes 1,770 (13.3) 11,537 (86.7) 1.00 1.00
No 158 (17.0) 756 (83.0) 0.76 (0.68,0.85)** 0.87 (0.61,1.35)
Note: **Significant at pB0.001.
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TB/HIV co-infection is associated with poor treatment
outcome (27). In addition, TB cases transferred out in
large numbers in northern Ethiopia were included in the
analysis, whereas the actual treatment outcome of this
group is not known. Thus, their inclusion in the computa-
tion would influence the report on TSR (13, 14, 22).
The TSR among re-treatment cases is much lower than
new PTB cases. This confirms previous studies where
re-treatment cases were significantly associated with un-
successful treatment outcome (11, 12, 28, 29). Moreover,
the current study revealed that there is high death rate
and failure rate among re-treatment cases compared to
the new ones. WHO recommended a microbial culture
and drug susceptibility test (DST) for all re-treatment TB
cases and new PTB cases who failed to convert sputum
examination results at the end of a second month of
follow-up (30). However, due to limited access to culture
and DST services in Ethiopia, the services were not
provided for MDR suspected cases; hence, the extent of
MDR among re-treatment cases was not known. More-
over, the high death and failure rate in this group in the
current study might also be due to high prevalence of
MDR-TB in the group (28, 29). Thus, the findings of the
study might warrant further investigation to determine
the extent of MDR-TB in Ethiopia. This could help in
giving a quick response to the current global challenge of
MDR-TB.
Reports from elsewhere revealed that the prevalence
of MDR-TB was more than 10-fold among previously
treated patients than untreated cases (28). Study results
from northern Ethiopia also indicated that previous
Table 4. Treatment outcomes of all pulmonary smear-positive (new plus re-treated cases) TB patients by districts in Arsi Zone,
Central Ethiopia, 19972011
Treatment outcomes for smear-positive pulmonary TB (N14221) TB/HIV co-infection
Total
PTB Cured rate
Treatment
success Defaulter rate Death rate
Failure
rate
Number of
tested HIV positive
Districts NN (%) N (%) N (%) N (%) N (%) NN (%)
Tiyo 131 58 (44.3) 113 (86.3) 12 (9.2) 4 (3.1) 2 (1.5) 42 4 (9.5)
Amigna 162 86 (52.4) 117 (72.2) 35 (21.6) 9 (5.6) 1 (0.6) 73 5 (6.8)
Aseko 373 259 (66.9) 310 (83.1) 41 (11.0) 21 (5.6) 1 (0.3) 138 2 (1.4)
Assala town 1,591 1,244 (76.7) 1,334 (83.8) 117 (7.4) 131 (8.2) 9 (0.6) 372 86 (23.1)
Ble Gezegar 256 128 (49.6) 214 (83.6) 24 (9.4) 18 (7.0) 0 (0.0) 58 4 (6.9)
Cholle 408 302 (72.8) 357 (87.5) 26 (6.4) 24 (5.9) 1 (0.2) 162 9 (5.6)
Digalutijo 970 715 (72.4) 829 (85.5) 55 (5.7) 79 (8.1) 7 (0.7) 247 16 (6.5)
Diksis 399 193 (47.9) 309 (77.9) 64 (16) 21 (5.3) 5 (1.3) 72 1 (1.4)
Dodota 1,425 911 (63.9) 1,149 (80.6) 108 (7.6) 158 (11.1) 5 (0.4) 180 36 (20)
Gololcha 444 303 (67.9) 401 (90.3) 35 (7.9) 7 (1.6) 1 (0.2) 222 5 (2.3)
Guna 466 238 (50.6) 344 (73.8) 80 (17.2) 40 (8.6) 2 (0.4) 98 2 (2)
Hetosa 840 570 (66.9) 688 (81.9) 84 (10.2) 66 (7.9) 2 (0.2) 218 20 (9.2)
H/Wabe 170 74 (43.3) 152 (89.4) 9 (5.3) 8 (4.7) 1 (0.6) 58 1 (1.7)
Jaju 961 730 (74.0) 821 (85.4) 59 (6.1) 77 (8.0) 4 (0.4) 253 11 (4.3)
L/Bilbilo 918 695 (74.1) 796 (86.7) 59 (6.4) 61 (6.6) 2 (0.2) 173 10 (5.8)
L/Hitosa 604 455 (73.6) 542 (89.7) 23 (3.8) 37 (6.1) 2 (0.3) 165 17 (10.3)
Merti 644 428 (65.5) 517 (80.3) 64 (9.9) 62 (9.6) 1 (0.2) 146 15 (10, 3)
Munesa 323 213 (65.1) 268 (83.0) 36 (11.1) 15 (4.6) 4 (1.2) 180 8 (4, 4)
Robe 996 657 (65.4) 821 (82.4) 92 (9.2) 78 (7.8) 5 (0.5) 169 14 (8.3)
Shirka 580 360 (61.6) 468 (80.7) 71 (12.1) 40 (6.9) 2 (0.3) 117 4 (3.4)
Sire 525 363 (68.5) 437 (83.2) 54 (10.3) 30 (5.7) 4 (0.8) 108 4 (3.7)
Sude 387 201 (51.3) 350 (90.4) 19 (4.9) 18 (4.7) 0 (0.0) 120 1 (0, 8)
Tena 166 98 (57.0) 115 (69.3) 28 (16.9) 17 (10.2) 6 (3.6) 68 5 (7.4)
Z/Dugda 320 233 (72.6) 296 (92.5) 8 (2.5) 15 (4.7) 1 (0.3) 101 3 (3)
Seru 167 91 (53.5) 140 (83.8) 13 (7.6) 12 (7.2) 2 (1.2) 87 5 (5.7)
Total 14,221 9,608 (67.5) 11,888 (83.6) 1,215 (8.5) 1,048 (7.4) 70 (0.5) 3,627 288 (7.9)
Note: Total cases include those under treatment success, defaulter, death and failure rates. L/Bilbilo: Lemu Bilbilo; L/Hitosa: Lode Hitosa;
Z/Dugda: Zuway Dugda.
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MDR-TB compared to new TB cases (31). The preva-
lence of MDR-TB is estimated to be between 1.6 and
1.8% among new and between 12 and 18% among re-
treatment cases in Ethiopia (8, 32). Establishing micro-
bial culture and DST services at least at referral hospital
to detect MDR-TB cases as early as possible and
initiating appropriate treatment is an urgent issue to be
addressed in Ethiopia.
The overall 8.6% 15-year average defaulter rate in
the current study was lower than reports from else-
where in and outside the country (10, 3335). However,
there are also other studies with lower rates than the
rate in this study (22, 23) and the global WHO target
of less than 5%. Patients returning for re-treatment
after defaulting were much more likely to default again
(26.6%) compared to new patients (7.0%). This finding
is in line with previous reports where such patients
w e r em o r el i k e l yt od e f a u l ta g a i nc o m p a r e dt on e w
cases (11, 12). Poor adherence to anti-TB treatment
due to defaulting and irregular treatment may lead to
more severe illness, treatment failure, relapse, longer
infection, drug resistance, and even death. Thus, default-
ing and irregular intake of anti-TB drugs are a chal-
lenge and concern for the individual patient as well
as for the community and they need to be addressed
properly.
The average 15-year failure rate (0.5%) in the pres-
ent study corroborates previous reports of 0.2, 0.5 and
0.3% failure rate in northwest and western Ethiopia
(14, 22, 23). However, it is lower than the 1.2% rate
among new PTB and the 6.4% among re-treatment
cases in southern Ethiopia (11), the 3.2% among new
PTB in north Ethiopia (12) and the 2.8% in China (25).
The large number of transfer outs and defaulters in
the present study might have exerted an influence on the
failure rate as it might be higher if the transfer outs were
evaluated and defaulters completed their treatment.
The present study indicated that TB patients in the
age range of 2549 and above 50 years, and those co-
infected with HIV were independently associated with
unsuccessful TB treatment outcome. This is supported
by other studies (11, 12, 33, 35, 36) where similar results
were observed. On the contrary, sex, area of residence,
and patient category showed no significant association
with unsuccessful TB treatment outcome, and this is
inconsistent with findings from other studies as well
(11, 13, 22, 35).
Findings from this study also illustrate a significant
variation in treatment outcomes among patients across
the 25 districts of the zone. The highest TSR (92.5%) with
lowest defaulter (2.5%) and failure (0.3%) rates in Zuway
Dugda district might indicate the role of effective TB
treatment in the reduction of defaulter cases and drug-
resistant strain. However, the lowest TSR (69.3%) with
highest failure (3.6%), defaulter (17%), and death (10.2%)
rates in Tena district might reflect the consequences of
poor TB treatment (3, 4).
The high death rate observed among districts with high
TB/HIV co-infection in the current study substantiates
previous reports of high mortality rate among TB/HIV
co-infected cases (3, 37). Overall, the variation in treat-
ment success, defaulter, death, and failure rates across
districts of the zone could be due to the real differences
in DOTS performance and disparity in quality of TB
control programme (11). Thus, the study warrants TB
programme managers and policy makers to identify
locality specific challenges to be addressed in order to
universally achieve the global WHO recommended rate
of 85% treatment success.
Although the study has established the usefulness of
facility-based data analysis of a 15-year period, it has
some limitations. This retrospective facility-based study
lacks inclusion of patients’ important variables such as
educational level, knowledge about TB, duration of the
treatment, distance from the treatment centre, family size,
family support, medication side effect, and income that
have been reported to have an association with TB
treatment outcomes (12, 13, 33). Because of the inherent
limitations of a retrospective study, incomplete data were
excluded from the analysis and this might affect the
results of this study. Moreover, counting all patients who
were treated with a full course of anti-TB drugs but with
missing records on their treatment outcomes as defaulters
could introduce bias as these patients might have com-
pleted the treatment, died, or failed.
Conclusions
DOTS expansion and improving population DOTS cover-
age in Arsi has led to a significant increase in treatment
success and a decrease in death and defaulter rates.
However, there is a major variation in treatment out-
comes across the 25 districts of the zone, so a district-
specific intervention strategy needs to be considered. The
low TSR among re-treatment cases might be due to a
high rate of MDR-TB among this group, and the issue
needs to be further investigated to identify the extent of
the problem.
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